FDA greenlights marketing of first Alzheimer’s blood test for some patients

by | May 16, 2025 | Uncategorized | 0 comments

Japan-based Fujirebio’s test, which helps doctors diagnose Alzheimer’s disease, is intended for patients with signs of cognitive decline.

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.